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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Pharmaceutical firm Roche has identified nine sites in the U.S. and Canada
for an observational study that will seek to answer key questions for the
company’s upcoming Phase 3 trial of a gene-silencing drug to treat
Huntington’s disease.
In a November 7 e-mail to the Huntington’s Disease Society of America
(HDSA) and other HD groups, the Swiss-based Roche announced that it
plans to carry out its HD Natural History Study, beginning by the end of
this year.
The HD Natural History Study is part of Roche’s global development
program for the gene-silencing drug, RG6042. The Natural History Study
will provide context for GENERATION HD1, the company’s Phase 3
clinical trial of RG6042, which will start enrolling volunteers in early 2019.
The HD Natural History Study will seek to deepen understanding of the
natural progression of HD, the role of the mutant huntingtin protein in the
disorder, and the assessment of biomarkers (signs of the disease measured
in patients) and their efficacy in predicting the effects of the drug.
Initial sites
Roche announced the sites listed below.
Canada
Centre for Movement Disorders, Toronto, ON
University of British Columbia, Vancouver, BC
U.S.
Columbia University, New York, NY
Georgetown University, Washington, D.C.
Hereditary Neurological Disease Center, Wichita, KA
Johns Hopkins University, Baltimore, MD
Rocky Mountain Movement Disorders Center, Englewood, CO
University of California Davis, Sacramento, CA
University of Texas, Houston, TX
“These sites are not fully activated nor recruiting yet, but we hope to
complete the final steps as quickly as possible,” wrote Mai-Lise Nguyen,
the patient partnership director for the Roche HD team, in the e-mail.
Roche will announce a total of eight additional sites in Germany and the
United Kingdom. It hopes to enroll 100 volunteers with early symptomatic
(Stage I and II) HD for the 15-month study (preceded by one month of
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screening). Participants must be between 25 and 65 at the start of the
study.
“I am pleased to share that setup has progressed well in all four countries
in which the HD Natural History Study is planned,” Nguyen added.
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The pivotal Phase 3 trial
In March, researchers announced the impressive results of the Phase 1/2a
trial for RG6042, completed in December 2017 with 46 participants in
Canada, Germany, and the United Kingdom. That trial tested primarily
safety and tolerability (click here to read more). Those results led Roche to
skip the usual Phase 2 trial and go directly to a pivotal Phase 3, named
GENERATION HD1.
RG6042 was developed by Ionis Pharmaceuticals, Inc., which partnered
with Roche in 2013. Roche now holds the license to the drug.
The GENERATION HD1 trial, to take place at 80 to 90 sites in 15
countries, will test whether RG6042 can slow, halt, and perhaps even
reverse HD symptoms in 660 volunteers over 25 months.
Each month, GENERATION HD1 participants will receive the drug or
placebo through a lumbar puncture. Physicians will also withdraw samples
of participants’ cerebrospinal fluid (CSF) to measure the level of mutant
huntingtin and other biomarkers.
Roche will announce GENERATION HD1 sites gradually in the coming
months.
Why a natural history study?
Roche officials said that the HD Natural History Study will start by the end
of 2018.
Participants in this observational trial will receive no drug. They will
undergo four lumbar punctures, with withdrawals of CSF for analysis.
They will also undergo MRI scans, blood tests, neurological examinations,
and two phone checkups. Like the volunteers in GENERATION HD1, they
will use digital monitoring devices.
Researchers have studied both the normal and mutant forms of the
huntingtin protein since the late 1990s. However, for GENERATION HD1,
Roche needs a deeper understanding of mutant huntingtin’s role in the
progression of the disease. Only in recent years have researchers started
examining the CSF of HD-affected individuals, so a critical question is how
mutant huntingtin levels change over time naturally.
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That data will provide context for researchers to interpret the
GENERATION HD1 data.
Furthermore, the RG6042 program involves just one Phase 3 trial, but
regulatory agencies frequently want a second. Thus, the HD Natural
History Study can help with the proper interpretation of Phase 3. Roche is
collecting additional data from an “open-label extension” study involving
all participants in the Phase 1/2a study. Each is receiving the drug.
“We’re really trying to understand better the natural history of the disease
and the predictive power of the biomarkers at baseline to predict clinical
outcome,” commented Scott Schobel, M.D., M.S., Roche clinical science
leader of product development, in a September 26 HDSA webinar on the
RG6042 program.

Dr. Scott Schobel announces GENERATION HD1 at the European
Huntington's Disease Network Meeting in Vienna, Austria, on September
16, 2018 (photo courtesy of HDBuzz.net).
Supporting GENERATION HD1
According to Frank Bennett, Ph.D., Ionis senior vice president of research
and franchise leader for neurological programs, the Natural History Study
aims to further understand the correlation between mutant huntingtin in
the CSF and other clinical measures of HD.
“Several studies have previously described the natural history of the
disease,” Dr. Bennett stated in an interview posted on the Ionis site on
September 17. “Many, however, have focused on specific clinical outcome
measures or changes in brain volume using imaging.”
The HD Natural History Study, he noted, will examine participants from
various angles: “This study will provide high-quality, longitudinal data to
help inform patients and clinicians about the course of HD, including wellvalidated clinical measures of HD, novel clinical outcomes, measurement
of mutant huntingtin in CSF and the use of wearable devices to measure
disease burden. Results from the HD Natural History study will provide
valuable information in support of our Phase 3 Generation HD1 study.”
(With another scientist, Dr. Bennett recently received the $3 million
Breakthrough Prize in Life Sciences. He also received the 2018 Hereditary
Disease Foundation Leslie Gehry Brenner Prize for Innovation in Science.)
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The Natural History Study participants could later have an opportunity to
take the drug.
“For all patients who complete the HD Natural History study, an openlabel extension study with the option of receiving RG6042 (no placebo
control) is planned, pending approval by authorities and ethics
committees/institutional review boards and if data support the continued
development of RG6042,” Nguyen stated.
An HDSA FAQ
As with GENERATION HD1, Roche will not require participants to live
within a certain distance of the study sites. However, a seven-page FAQ on
the Roche program posted by HDSA on October 17 states that “the travel
burden will likely be considered during the screening” of volunteers.
“A major move or a long-distance commitment could create additional
stress on a participant and his/her loved ones,” the document continues.
“Excessive travel may also make it more likely for someone to drop out of a
trial, which could hamper the success of GENERATION-HD1 or the HD
Natural History Study. Clinical studies are subject to international,
national and local laws and regulations.
“Additionally, factors such as institutional site policies and health
insurance may impact your ability to relocate and be accepted into one of
the study sites. Eligibility and enrollment are ultimately decided by the
study investigator at each site, who takes into account all these factors and
may also wish to speak to you or your local HD specialist for more
information.”
The FAQ addresses many of the hundreds of questions posed by the HD
community before, during, and after the September 26 webinar (click
here to read more). Topics include study eligibility requirements, the
potential risks of RG6042, and the procedures, examinations, and other
activities of the clinical appointments for both GENERATION HD1 and the
Natural History Study.
‘Difficult to predict the outcome’
The imminence of the Natural History Study indicates that Roche is on
track to carry out its plan to gradually announce GENERATION HD1 sites
in the coming months and enroll the first patients in early 2019.
People can track the progress of the Natural History Study at
ClinicalTrials.gov. That site and HDSA’s HDTrialFinder will also provide
information on GENERATION HD1.
Regarding the duration of GENERATION HD1 and next steps if the drug
works, the HDSA FAQ points out that “it’s very difficult to predict the
outcome and timing of a large international drug study.[…] If the results
are promising, approvals would need to move through regulatory health
authorities.”
For now, the watchwords for the HD community are commitment,
patience, and hope.
(Disclosure: I hold a symbolic amount of Ionis shares.)
Posted by Gene Veritas at 4:35 PM
Labels: biomarkers , clinical trials , CSF , gene-silencing , GENERATION HD1 , HD
Natural History Study , Huntington's disease , Ionis , lumbar puncture , mutant
huntingtin , observational study , RG6042 , Roche , symptoms , treatments

curehd.blogspot.com/2018/11/roche-announces-first-sites-for-key.html

4/5

11/18/21, 1:48 PM

At Risk for Huntington's Disease: Roche announces first sites for key Huntington’s disease observational study

No comments:
Post a Comment

Newer Post

Home

Older Post

Subscribe to: Post Comments (Atom)

curehd.blogspot.com/2018/11/roche-announces-first-sites-for-key.html

5/5

